NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD
Taking everything into account, AKRO scores 2 out of 10 in our fundamental rating. AKRO was compared to 566 industry peers in the Biotechnology industry. While AKRO seems to be doing ok healthwise, there are quite some concerns on its profitability. AKRO has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -30.52% | ||
ROE | -33.6% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Altman-Z | 25.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 19.38 | ||
Quick Ratio | 19.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
45.61
+2.57 (+5.97%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.84 | ||
P/tB | 4.84 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -30.52% | ||
ROE | -33.6% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 5550% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 19.38 | ||
Quick Ratio | 19.38 | ||
Altman-Z | 25.66 |